A Novartis experimental drug in clinical trial aims to block liver cancer growth

Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.